Jaguar Health, Inc. Receives Nasdaq Notification Regarding Publicly Held Shares Requirement
San Francisco, CA, May 4, 2026 — Jaguar Health, Inc. (“Jaguar Health” or the “Company”) has received a formal written notice from The Nasdaq Stock Market LLC (Nasdaq) which could have significant implications for the company’s listing status and may be of critical interest to shareholders and potential investors.
Key Points from the SEC 8-K Filing
- Nasdaq Non-Compliance Notification: On May 1, 2026, Jaguar Health received a notification from Nasdaq’s Listing Qualifications Department indicating non-compliance with Nasdaq Listing Rule 5550(a)(4), which requires a minimum of 500,000 publicly held shares for continued listing on the Nasdaq Capital Market.
- Reason for Non-Compliance: The Company recently effected a 1-for-35 reverse stock split of its issued and outstanding common shares (par value \$0.0001 per share) on April 30, 2026. As a result, the number of publicly held shares fell to approximately 401,226, below the required threshold.
- Additional Compliance Issues: Nasdaq staff also noted the Company remains out of compliance with the minimum \$1.00 bid price requirement. Even if the share count issue is resolved, the Company must demonstrate a closing bid price of at least \$1.00 per share for 10 consecutive business days (Nasdaq may extend this up to 20 days at its discretion).
- Actions Taken by Jaguar Health: On May 4, 2026, certain third-party investors exercised existing pre-funded warrants to purchase common stock, increasing the number of publicly held shares to 513,939, and the total issued and outstanding shares to 513,974.
- Awaiting Nasdaq Confirmation: The Company is currently awaiting formal confirmation from Nasdaq that these recent transactions have brought it back into compliance with the Publicly Held Shares Requirement.
What Shareholders Need to Know
- Potential Delisting Risk: Failure to maintain the required minimum number of publicly held shares and meet the minimum bid price could result in Jaguar Health being delisted from the Nasdaq Capital Market. Delisting typically has a negative impact on share liquidity and price, and may limit access to capital markets.
- Reverse Stock Split: The recent 1-for-35 reverse split was a significant corporate action likely intended to address the bid price deficiency, but it also temporarily reduced the number of publicly held shares below Nasdaq’s threshold.
- Price Sensitivity: The outcome of Nasdaq’s review—whether the Company is deemed back in compliance or faces further action—could materially affect the share price. Investors should monitor subsequent disclosures from Jaguar Health and Nasdaq closely.
- Corporate Governance: The Company’s response, including the exercise of pre-funded warrants, demonstrates active efforts to address compliance issues, but additional measures may be necessary to stabilize and improve share price performance.
Additional Details
- Ticker Symbol: JAGX
- Exchange: The Nasdaq Stock Market
- Headquarters: 200 Pine Street, Suite 400, San Francisco, CA 94104
- CEO & President: Lisa A. Conte
- Industry: Pharmaceutical Preparations
- SEC File Number: 001-36714
Conclusion
This Nasdaq notification represents a potentially material event for Jaguar Health and its investors, with possible impacts on the company’s market listing and share value. The Company’s prompt actions to restore compliance are a positive sign, but until Nasdaq provides formal confirmation, shareholders face ongoing uncertainty. Any further updates from the Company or Nasdaq could result in significant share price movements.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. The information above is based on public filings as of May 4, 2026, and subsequent developments may alter the Company’s situation.
View Jaguar Health, Inc. Historical chart here
